US-based biotechnology company Imunon has reported positive results from its Phase II OVATION 2 trial of IMNN-001 for ovarian ...

As I mark my first year as President and CEO of IMUNON, I am thrilled to share the progress we have made in advancing our mission to transform cancer treatment. With robust fundamentals and ...

Imunon (IMNN) announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 7,222,223 ...

Retail buzz around Imunon rose sharply Thursday after the clinical-stage biotech company said it will no longer pursue a previously planned public offering. Imunon formally requested to retract its ...

Imunon, Inc. (NASDAQ:IMNN), a company operating in the biotechnology sector, is part of key market indexes such as the Top ...

Results, presented simultaneously in oral presentation at ASCO 2025 and in peer-reviewed Gynecologic Oncology, suggest very meaningful survival effect of IMNN-001 in women HRP and HRD positive, ...

IMUNON initiates Phase 3 OVATION 3 study for IMNN-001 in advanced ovarian cancer; Phase 2 data accepted for ASCO presentation. IMUNON, Inc. has initiated the first trial site for its Phase 3 ...

About IMNN-001 Immunotherapy Designed using IMUNON's proprietary TheraPlas ® platform technology, IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that ...

LAWRENCEVILLE, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has ...

Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response Results, presented simultaneously in oral ...